Table 1.
Vaccine antigens | Gene | Site of integration |
Promoter | 5′/3′ Regulatory elements |
% TSP expression |
Functionality assay | Lab/year |
---|---|---|---|---|---|---|---|
Cholera toxin | CtxB | TrnI/trnA | Prrn | ggagg/ TpsbA | 4% | GM—1 ganglioside binding assay |
Daniell 2001 |
Tetanus toxin |
TetC (bacterial and synthetic) |
TrnV/rps12/7 | Prrn | T7 gene 10a, atpBb / TrbcL |
25% a, 10% b | Positive systemic immune response |
Maliga 2003 |
Canine parvovirus (CPV) | CTB—2L21/GFP—2L21 | TrnI/trnA | Prrn | PpsbA/TpsbA | 31.1%, 22.6% | Immune response | Daniell, Veramandi 2004 |
Anthrax protective antigen | Pag | TrnI/trnA | Prrn | PpsbA/TpsbA | 4%–5% | Macrophage lysis assay | Daniell 2004 |
Plague vaccine | CaF1~LcrV | TrnI/trnA | Prrn | PpsbA/TpsbA | 14.8% | ND | Daniell 2003 |